High Glucose Time, Low Variability Tied to Advanced CKM Syndrome

Continuous glucose monitoring identified four distinct glycaemic phenotypes among 2,491 adults aged 60 years or older with Type 2 diabetes, according to a study published in November 2026 in the Journal of Diabetes.

Participants had maintained stable glucose-lowering treatment regimens for three months before undergoing seven days of blinded monitoring. Researchers at the Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine collected clinical, biochemical, and device data for the analysis.

Cardiovascular-kidney-metabolic syndrome was classified using American Heart Association criteria. Stages 3 and 4 constituted advanced disease across the study cohort.

Overall, 65.0% of participants had advanced cardiovascular-kidney-metabolic syndrome. Investigators divided participants into four phenotypes based on whether their time above range and mean amplitude of glycemic excursions sat above or below study medians of 27.0% and 5.3 mmol/L.

Participants with both high time above range and high variability showed the poorest overall glycaemic control. That group recorded a median glycated hemoglobin of 9.1% alongside the lowest time in range.

However, the phenotype defined by high time above range and low variability showed the strongest association with advanced disease. That specific group demonstrated a 73.3% prevalence of advanced cardiovascular-kidney-metabolic syndrome.

The high time above range and low variability phenotype exhibited a fasting hyperglycaemia-dominant pattern. This group displayed the highest fasting plasma glucose and triglyceride levels among all four categories.

Researchers noted this phenotype also showed the lowest insulin sensitivity. Hang Su and colleagues used an outcome-guided workflow combining XGBoost feature-importance analysis with correlation analysis to construct the classifications.

“CGM-derived glycemic phenotypes demonstrated distinct metabolic profiles and differential associations with advanced CKM syndrome,” the authors said in the Journal of Diabetes.

Study authors suggested that device-derived phenotypes characterize metabolic heterogeneity that conventional glycaemic indicators miss. Conventional markers often fail to capture specific risk patterns in older populations.

Prospective studies are required to assess the value of these phenotypes in predicting disease progression. Investigators aim to determine whether these classifications improve the forecasting of cardiorenal outcomes in older patients.

“Prospective studies are needed to assess their value in predicting CKM progression and cardiorenal outcomes,” the researchers concluded in the Journal of Diabetes.

How many patients participated in the analysis? Researchers evaluated clinical and device data from 2,491 adults aged 60 years or older with Type 2 diabetes, as reported by Hang Su et al.

What criteria defined advanced disease? Investigators classified cardiovascular-kidney-metabolic syndrome using American Heart Association criteria, designating Stages 3 and 4 as advanced disease.

Which phenotype showed the highest disease prevalence? The group characterized by high time above range and low glycemic variability showed a 73.3% prevalence of advanced cardiovascular-kidney-metabolic syndrome.